Other inhibitors of EGFR/ERBB1 tested for HNC treatment are dacomitinib and vandetanib. When used with radiotherapy, dacomitinib reduces tumor volume in HNSCC, while vandetanib, and cisplatin radiosensitizes tumor cells. Here, EGFR is linked to neoplasm.